Editorial
Beta blockers prevent cardiac death following a myocardial infarction: So why are so many infarct survivors discharged without beta blockers?

https://doi.org/10.1016/S0002-9149(96)00428-6Get rights and content

References (20)

There are more references available in the full text version of this article.

Cited by (41)

  • Beta-blockers reduced the risk of cardiac rupture in patients with acute myocardial infarction: A meta-analysis of randomized control trials

    2017, International Journal of Cardiology
    Citation Excerpt :

    There are neither means of predicting or monitoring CR, nor an effective therapy. Beta-blockers have long been a mainstay for the treatment of acute MI [5]. Clinical studies have shown that early beta-blockers treatment in acute MI patients reduce total mortality and sudden cardiac death [6,7].

  • Preoperative Evaluation

    2015, Murray and Nadel's Textbook of Respiratory Medicine: Volume 1,2, Sixth Edition
  • Early intravenous beta-blockers in patients with acute coronary syndrome-A meta-analysis of randomized trials

    2013, International Journal of Cardiology
    Citation Excerpt :

    Beta-blockers have long been a mainstay for the treatment of acute coronary syndromes (ACS) [1].

  • Impact of intravenous Beta-Blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction

    2004, Journal of the American College of Cardiology
    Citation Excerpt :

    Although detailed explanations as to why beta-blockers were withheld were not collected, it is unlikely that strict contraindications were present in most patients. It is well known that beta-blockers are frequently under-prescribed in the peri-infarct period (24,25), possibly reflecting physicians' concerns about their safety in the AMI setting and misconceptions regarding absolute versus relative contraindications (26). In the present study, intravenous beta-blocker administration was safe, being associated only with a slight increase in the incidence of transient peri-procedural heart failure, without increases in adverse events such as bradyarrhythmias or severe hypotension.

View all citing articles on Scopus
View full text